Although preserved internal jugular veins can become occluded after neck dissection, we have not experienced free jejunal flap necrosis when the veins were used as recipient vessels. Thus, we investigated whether using the internal jugular veins as the recipient vessel for free jejunal flap transfer after neck dissection might contribute to postoperative internal jugular vein patency. This retrospective cohort study involved patients who underwent internal jugular vein-preserving neck dissection for hypopharyngeal malignant tumors. We identified and assessed 2 treatment groups: patients with and without preserved internal jugular vein as the recipient vein. To guarantee 80% power for detecting differences between groups using the chi-squared test at a 5% significance level, the enrollment continued until at least 40 patients were included. The primary outcome assessed was internal jugular vein patency on post-contrast computed tomography scans 3 months post-operatively. Preoperative radiation therapy, central venous catheter, left side, and pectoralis major myocutaneous flap reconstruction were included as covariates in the multivariable model. During this period, 123 neck dissections were conducted in 80 eligible patients. Using the internal jugular veins as the recipient vein for free jejunal flap transfer contributed to 19% improvement in patency. Supplemental analysis with additional covariates also showed that patency was significantly improved by 15%. We strongly recommend that the internal jugular veins of the dissected side should be used as the recipient vein to improve postoperative patency of internal jugular veins.
21 October 2026 in Journal of Biomedical Materials Research Part A
Prosthetic heart valve development consists of several branching, innovative strategies to mediate the complex native environment that wears down valve durability. Anti‐calcification treatments are being applied to pericardial tissue, durable polymers are being developed that mitigate oxidative degradation and stress cracking, and heart valve tissue engineering has introduced resorbable scaffolds that can develop into stable, functional tissue. In each case, an increasing breadth of strategies is being developed to curb the persistent issue of valve deterioration. This study aimed to synthesize and characterize an ascorbic acid‐containing polyurethane to impart antioxidant properties to degradable scaffolds for tissue engineered heart valve (TEHV) replacement. Blends of poly(carbonate‐ascorbic acid) urethane (PCAU) and poly(carbonate urethane) urea (PCUU) were fabricated into microporous scaffolds to evaluate the impact of PCAU in vitro on mechanics, degradation, cell viability, calcification, bacterial adhesion, and in vivo on native tissue response in a juvenile rat subcutaneous model. PCAU blended with PCUU in a 25:75 ratio (PCAU‐25) had mechanical properties similar to PCUU, while higher concentrations of PCAU were not mechanically robust. PCAU‐25 showed greater reactive oxygen species (ROS) inhibition and degradation, and reduced calcification and bacterial adhesion in vitro. In a juvenile rat subcutaneous model, both PCUU and PCAU‐25 groups showed negligible calcification after 4 weeks. PCAU‐25, however, showed much greater cell infiltration and immune response, possibly due to an accelerated rate of degradation. PCAU‐25 was then fabricated into a polymeric valve scaffold and underwent basic mechanical and hydrodynamic performance assessment that demonstrated function similar to PCUU valves previously reported. These findings demonstrate proof‐of‐concept for a new polyurethane formulation incorporating ascorbic acid for antioxidant bioactivity and translatability into a functional TEHV scaffold.
Compliance matching of tissue engineered vascular grafts (TEVGs) is a promising technique to combat common failure modes seen clinically in small diameter vascular procedures like coronary artery bypass grafting (CABG). However, despite the influence of sex on vascular response to injury, the role of biological sex on the success of TEVG innovations such as compliance matching, namely in long-term remodeling, has been understudied. In this study we fabricated compliance matched TEVGs (CM TEVGs) and hypocompliant TEVGs (Hypo TEVGs) by adjusting the thicknesses of a high polyester urethane urea (PEUU) containing layer (80:20 PEUU:Gelatin) and a low PEUU containing layer (20:80 PEUU:Gelatin). All grafts were implanted into the abdominal aorta of both male and female Sprague Dawley rats (n = 4) as interposition grafts for 6 months and monitored using in vivo ultrasound. Upon explant, key outcomes of long-term remodeling were assessed via immunohistochemistry, multiphoton imaging, and qRT-PCR. CM TEVGs were confirmed to be compliance matched to native aorta both in vitro and in vivo upon implant. After remodeling, CM TEVGs had increased degradation and decreased calcification compared to Hypo TEVGs. CM TEVGs had increased mature VSMC genes (Acta2, Myh11, Cnn1) in males and decreased macrophage presence (CD68) in females. Independent of graft type, females had increased intimal thickening, decreased luminal presence of mature VSMCs, and increased fibrillar collagen deposition compared to males in both CM and Hypo TEVGs. Our results suggest that long-term remodeling outcomes in response to compliance matching are dependent on biological sex at both the tissue and cellular level.